PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
latest PatentVest Pulse report, “ The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine. ” The report provides a comprehensive analysis of the rapidly evolving amylin drug landscape, a mechanism once considered commercially unviable that is now at the center of global pharmaceutical strategy. Over the past eighteen months, more than $19 billion in deal value has been committed across the amylin space, with major pharmaceutical companies, including Novo Nordisk, Eli Lilly, Roche, Pfizer, and AbbVie, actively building positions. The report highlights: Nearly 40 amylin receptor agonist programs currently in development worldwide The first GLP-1/amylin combination therapy approaching FDA decision Clinical data demonstrating up to 20%+ weight loss with amylin-based therapies The emergence of oral small-molecule amylin programs as a potential market-expanding force The critical role of patent strategy in deter
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo launches $249 Wegovy subscription, undercutting Lilly as shares fall 30% [Yahoo! Finance]Yahoo! Finance
- PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment [TheStreet.com]TheStreet.com
- Wegovy Subscription Launched—Here’s How Much It Could Save Users A Year [Forbes]Forbes
- Popular Weight-Loss Drug Wegovy Unveils Subscription Service [MSNBC.com]MSNBC.com
- Novo Nordisk launches Wegovy subscription program [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website